Avonex

The good, the bad and the ugly

Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down. ... The appraisal rejected four other interferons - Biogen’s Avonex and long-acting variant Plegridy, Bayer’s Betaferon, and Merck Serono’s Rebif - as well as Teva’s

NICE backtracks on Biogen's multiple sclerosis drug Zinbryta

Zinbryta is dosed once a month - less frequently than other MS drugs such as Biogen's own Plegridy and Avonex - and is formulated as a subcutaneous injection that can be administered

Biogen's CEO Scangos to step down

2015, although older injectable MS treatment Avonex (interferon-beta-1a) fell 2% to $606m. ... Long-acting Avonex follow-up Plegridy continued to gain ground - with sales up 65% to $123m - and there were also strong gains for Biogen's haemophilia drugs

Biogen multiple sclerosis drug flunks clinical trial

interferon products Avonex and Plegridy and lower-than-hoped-for volume growth for oral therapy Tecfidera (dimethyl glutamate). .

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]